Core Insights - Clearmind Medicine is advancing its proprietary compound MEAI, a non-hallucinogenic neuroplastogen, as a potential next-generation treatment for obesity, targeting the psychological roots of eating behaviors [1] - The obesity treatment market is projected to exceed $100 billion, indicating significant growth potential for innovative therapies like MEAI [1] Company Overview - Clearmind Medicine is a clinical-stage biotech company focused on developing novel therapeutics to address under-treated health issues, particularly obesity [1] - MEAI is designed to disrupt rigid behavioral patterns, promote cognitive flexibility, and enhance neuronal plasticity while providing metabolic benefits [1] Mechanism of Action - Unlike GLP-1-based treatments that primarily target gut hormones, MEAI works directly in the brain by modulating the monoaminergic system, addressing compulsive eating behaviors and food addiction [1] - Pre-clinical studies indicate that MEAI can modulate energy balance, boost fat burning, improve insulin sensitivity, and significantly decrease fat mass while preserving lean muscle mass [1] Comparative Analysis - MEAI shows a potential weight loss profile of approximately 20% reduction in pre-clinical studies, prioritizing fat loss and muscle preservation, compared to GLP-1 drugs which show a 15-22% reduction often accompanied by muscle loss [1] - MEAI has a favorable safety profile with no reported sedation or hyperactivity, contrasting with common gastrointestinal issues associated with GLP-1 drugs [1] Strategic Developments - Clearmind has filed new patent applications targeting obesity and metabolic disorders and is collaborating with Polyrizon to develop an intranasal formulation for enhanced delivery [1] - The company is progressing in its FDA-approved Phase I/IIa trial for alcohol use disorder, with successful cohort completions and upcoming data readouts [1] Future Outlook - Clearmind's leadership emphasizes MEAI's potential as a safer, more effective alternative to current therapies, focusing on behavioral aspects of obesity that hormonal drugs often overlook [1] - The combination of pre-clinical and clinical evidence, intellectual property advancements, and strategic partnerships positions MEAI as a promising solution for sustainable weight management [1]

Core Viewpoint - Clearmind Medicine Inc. has entered into a development agreement with Polyrizon Ltd. to enhance the bioavailability and clinical advancement of its lead compound MEAI for addiction-related and other CNS disorders [1][2][3] Group 1: Collaboration Details - The agreement involves the application of Polyrizon's proprietary intranasal hydrogel technology to develop an optimized formulation of Clearmind's MEAI [2][3] - The collaboration aims to leverage the advantages of intranasal delivery for CNS-targeted therapeutics, which include enhanced nasal residence time, targeted delivery, and bypassing first-pass metabolism [3][5] Group 2: Company Insights - Clearmind is focused on discovering and developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including addiction and mental health disorders [1][6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Group 3: Technology Overview - Polyrizon specializes in developing innovative medical device hydrogels for nasal delivery, which can provide a barrier against viruses and allergens [7] - Their proprietary Capture and Contain™ hydrogel technology aims to improve bioadhesion and retention at the nasal deposition site for drug delivery [7]

Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]

As filed with the Securities and Exchange Commission on December 5, 2025. Registration No. 333-291817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organiz ...

As filed with the Securities and Exchange Commission on November 26, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 ...

As filed with the Securities and Exchange Commission on September 13, 2023. Registration No. 333-273293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organ ...

As filed with the Securities and Exchange Commission on July 25, 2023. Registration No. 333-273293 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification Number) | 101 – 1220 West 6 Avenue Vancouver, B ...

As filed with the Securities and Exchange Commission on July 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 – 12 ...

As filed with the Securities and Exchange Commission on March 28, 2023. Registration No. 333-270859 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organizat ...

As filed with the Securities and Exchange Commission on March 27, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CONFIDENTIAL SUBMISSION ON FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. ☒ If this form is filed to register additional securit ...